-
(单词翻译:双击或拖选)
Washington
14 October 2007
An international team of scientists say they are on the verge1 of developing the first blood test for Alzheimer's disease which experts hope will help doctors identify patients with the memory-robbing disease in its earliest stages. Experts say the blood test identifies proteins that are unique to people with Alzheimer's and appear years before there are major symptoms. VOA's Jessica Berman reports.
One of the early signs of Alzheimer's disease is forgetfulness. But it can be caused by a number of benign2 conditions, including aging itself.
The first place most families take their elderly relative for evaluation3 is not an expert neurologist, according to Todd Golde, a professor of neuroscience at the Mayor Clinic in Jacksonville, Florida, but the family physician.
"And for those people, the diagnosis4, and an accurate diagnosis, is a challenge," said Todd Golde. "And so I think that would bring a more uniform and consistent diagnosis to across a wider section of people receiving care for Alzheimer's."
Researchers in the United States, Germany and Sweden are working on a blood test, which they describe in the latest issue of of the journal, Nature Medicine.
Using computer analysis, investigators5 identified 18 proteins that the body uses to communicate with immune and nervous system cells. Researchers compared the proteins in healthy individuals to those with advanced Alzheimer's.
The test was 90 percent accurate in diagnosing the disease in its early stages.
Tony Wyss-Coray, professor of medicine at Stanford University and the report's senior author, says more research is needed to confirm the study's findings. But he believes a blood test may soon be available that could help doctors make a complex diagnosis.
"This might be feasible in a relatively6 short period of time to have actually a blood test that can at least help in diagnosing Alzheimer's disease and may even be able predict whether a person will develop it if they have memory complaints right now," said Tony Wyss-Coray.
Experts say such information would mean patients would be able to begin early therapy to delay the decline of Alzheimer's, and help families prepare for the devastation7 of a progressive and fatal illness.
Wyss-Coray is scientific advisor8 of Satoris Group in San Francisco, California which he founded to develop and market an Alzheimer's test kit9, when one becomes reliable. Todd Golde of the Mayo Clinic is an advisor to Satoris and has a financial interest in the company.
1 verge | |
n.边,边缘;v.接近,濒临 | |
参考例句: |
|
|
2 benign | |
adj.善良的,慈祥的;良性的,无危险的 | |
参考例句: |
|
|
3 evaluation | |
n.估价,评价;赋值 | |
参考例句: |
|
|
4 diagnosis | |
n.诊断,诊断结果,调查分析,判断 | |
参考例句: |
|
|
5 investigators | |
n.调查者,审查者( investigator的名词复数 ) | |
参考例句: |
|
|
6 relatively | |
adv.比较...地,相对地 | |
参考例句: |
|
|
7 devastation | |
n.毁坏;荒废;极度震惊或悲伤 | |
参考例句: |
|
|
8 advisor | |
n.顾问,指导老师,劝告者 | |
参考例句: |
|
|
9 kit | |
n.用具包,成套工具;随身携带物 | |
参考例句: |
|
|